Drug Type TCR-T Cell therapy |
Synonyms TSC 102, TSC-102(HLA-A*03:01), TSC102 |
Target |
Action modulators |
Mechanism CD45 modulators(Leukocyte common antigen modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Preclinical | United States | 01 Dec 2024 | |
Acute Myeloid Leukemia | Preclinical | United States | 01 Dec 2024 | |
Myelodysplastic Syndromes | Preclinical | United States | 01 Dec 2024 |